MarketBeat
23 May 2026, 01:02 UTC · 2h ago
Source · https://www.marketbeat.com/instant-alerts/definium-therapeutics-eyes-key-dt-120-depression-data-advances-anxiety-program-2026-05-22/
Read source
Story key points
4 claims · impact-rated
Definium Therapeutics expects to release Phase III data for DT-120 in major depressive disorder (MDD) later this quarter. — Phase III readouts are primary binary catalysts for biotech valuations, potentially leading to significant price swings based on success or failure.
+0.80The company reports that Phase III GAD studies show lower than expected dropout rates and standard deviation, increasing confidence in detecting a five-point placebo-adjusted change. — Higher statistical confidence in a primary endpoint reduces the risk of a failed trial and suggests a cleaner path to approval.
+0.50Definium plans to initiate a PTSD study next year to target an estimated 13 million U.S. patients. — Expanding the addressable market into PTSD provides long-term growth optionality and diversifies the pipeline.
+0.30Search tags
The company is utilizing SPRAVATO as a commercial analog for pricing, with that drug costing between $30,000 and $70,000 per year. — Providing a high-value pricing benchmark helps analysts model potential peak revenues and commercial viability.
+0.20Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is advancing multiple Phase III trials with positive early indicators of dropout reduction and high confidence in detecting clinical benefits.
No ticker relationship head found.
